Designing with biology: re-educating urban skin tolerance through biotechnology

For many years, biotechnology in personal care was mainly framed as a more sustainable way to produce known molecules or replace conventional materials. This remains essential, but the next phase is broader: biotechnology is allowing the industry to move from simply using biology towards designing with biology. In cosmetics, this means creating active ingredients that interact with specific biological pathways to address mechanisms that conventional approaches could not fully reach.

Sensitive and hyperreactive skin is a clear example. Urbanisation has fundamentally changed the skin’s operating environment. Contemporary lifestyles expose the skin to a sustained cocktail of indoor and outdoor pollutants, including fine particulate matter, volatile organic compounds, polycyclic aromatic hydrocarbons and combustion by-products. These aggressors can contribute to persistent low-grade inflammation, barrier dysfunction and immune hyperreactivity, which clinically appear as redness, stinging, tightness and chronic sensitivity (1-3).

This is especially relevant indoors. Urban consumers often spend most of their time inside enclosed environments, where pollutant levels may exceed outdoor concentrations and where cooking, building materials, household products and infiltrating outdoor particles create a continuous exposure scenario (4-8). The biological consequence is not simply inflammation. Inflammation is the output. The deeper issue is that the skin’s immune system may lose part of its ability to distinguish harmless environmental stimuli from genuine threats.

Traditional sensitive skin strategies have largely focused on immediate relief: soothing, calming, blocking or reducing visible symptoms (9). These approaches remain valuable, but they often do not address the immune dysregulation driving the condition. If chronic pollutant exposure lowers the threshold for immune response, the next generation of cosmetic actives should not only silence the signal. They should help the skin relearn tolerance.

This is where Langerhans cells become a compelling biological target. These dendritic cells, representing around 3–5% of epidermal cells, act as pivotal immune decision-makers in the skin. In healthy conditions, they maintain a steady-state tolerogenic phenotype: alert but calm, able to discriminate between threats and harmless stimuli (10, 11). Under chronic pollution-related stress, however, they may shift towards an activated immunogenic state, promoting immune maturation, migration and the release of pro-inflammatory mediators (12).

A biotechnology-based strategy can be designed to interact with this immune decision-making system. One emerging approach is based on GM-CSF, a human protein produced endogenously by keratinocytes, fibroblasts and endothelial cells. GM-CSF is involved in the differentiation, survival and functional programming of Langerhans cells, making it a key biological signal for maintaining immune tolerance (13). When this signal is eroded by chronic stress, pollution, UV exposure or ageing, Langerhans cells may default towards reactivity.

Through plant-based recombinant protein technology, it is now possible to produce a human GM-CSF-inspired cosmetic active using plants as biofactories. This plant expression system offers a eukaryotic cellular environment suitable for correct protein processing, while supporting a clean, scalable and non-animal production model. This is an example of biotechnology not only as a greener manufacturing route, but as a tool to design a precise biological intervention.

Mechanistically, this active binds to GM-CSF receptors on Langerhans cells, activating the NF-κB pathway and the transcription factors RELB and SOX4. These signals help guide Langerhans cells towards a tolerogenic, non-inflammatory phenotype, characterised by lower expression of co-stimulatory molecules such as CD80/86 and the migratory receptor CCR7. Once calmed, Langerhans cells support the release of TGF-β and help reduce pro-inflammatory cytokines including TNF-α, IL-8 and IL-6. The result is a tolerogenic reset: a shift from immune overreaction towards a more balanced skin microenvironment.

This immune recalibration is also connected to barrier quality. Our in vitro studies using reconstructed human epidermis containing Langerhans cells showed that, under an Indoor Pollution Challenge, the active normalised immune activation markers, restored tolerogenic mediators and supported barrier-related proteins such as Filaggrin, Loricrin, Cadherin-1 and Claudin-4. This highlights a potential direction for future cosmetics: immune tolerance and barrier resilience should not be treated as separate territories, but as mutually reinforcing mechanisms (14).

Clinical evaluation in volunteers with hyperreactive skin illustrates a potential application of this biotechnology approach. Twice-daily application in placebo-controlled studies showed visible improvements in redness and erythema, together with reductions in functional signs such as burning, itching, stinging and tightness. In vivo analysis also confirmed a reduction in skin reactivity markers including IL-6, IL-8 and TNF-α (14).

This example points towards the next phase of biotechnology in personal care. The future will not only be defined by replacing ingredients with more sustainable alternatives, but by enabling mechanisms that were previously inaccessible to cosmetic science. Biotechnology can help design actives that speak the language of the skin: restoring tolerance, improving communication with the environment and supporting resilience against chronic urban stress.

In this sense, biotechnology becomes more than a source of ingredients. It becomes a way to design with biology.